RARE ULTRAGENYX PHARMACEUTICAL INC Other Situations 8-K Filing 2023 - FDA Protocol Amendment Ultragenyx Pharmaceutical announced a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC